Shuang Cai

Southern Medical University, Shengcheng, Guangdong, China

Are you Shuang Cai?

Claim your profile

Publications (6)16.04 Total impact

  • Zan Teng · Lei Wang · Jingdong Zhang · Shuang Cai · Yunpeng Liu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Glutathione S-transferase M1 (GSTM1) polymorphism has been proven to be associated with risks of several cancers. However, previous studies on the association between GSTM1 polymorphism and colorectal cancer risk in Chinese population reported controversial results. We performed a meta-analysis of 13 studies which were identified through the literature search in PubMed and Wanfang databases. The strength of the association between GSTM1 polymorphism and colorectal cancer risk was measured by odds ratio (OR) with corresponding 95 % confidence interval (95 % CI). Overall, GSTM1 null mutation was significantly associated with a risk of colorectal cancer in Chinese population (OR = 1.37, 95 % CI 1.12 to 1.68, P = 0.002). Sensitivity analyses by omitting those studies in turns did not materially alter the overall pooled ORs. The cumulative meta-analyses further showed a trend of an obvious association between GSTM1 null mutation and risk of colorectal cancer in Chinese population as information accumulated by year. The findings from our meta-analysis suggest that GSTM1 null mutation is significantly associated with a risk of colorectal cancer in Chinese population.
    Tumor Biology 11/2013; 35(3). DOI:10.1007/s13277-013-1281-2 · 3.61 Impact Factor
  • Source
    Lei Wang · Shuang Cai · Zan Teng · Xin Zhao · Xinyue Chen · Xiaojuan Bai ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent epidemiological studies suggest that treatment with insulin may promote cancer growth. The present systematic review and meta-analysis of published observational studies was conducted to assess the risk of cancer during treatment with insulin.Materials and methodsA compressive search was conducted through MEDLINE, PubMed, Web of Science, EMBASE, and Chinese Biomedical Literature databases (CBM). Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated with a random-effects model. A total of four studies with one case-controls study and three cohort studies comparing the insulin therapy and colorectal cancer susceptibility were identified. When all four studies were analyzed, the summary RRs were 1.61 (95% CI = 1.18--1.35) in a random-effects model for individuals with insulin therapy, compared with individuals without insulin therapy, which suggests a statistically significant association between insulin use and colorectal cancer. Our findings provides the evidence that insulin therapy may contribute to the risk of colorectal cancer.Virtual slidesThe virtual slide(s) for this article can be found here:
    Diagnostic Pathology 10/2013; 8(1):180. DOI:10.1186/1746-1596-8-180 · 2.60 Impact Factor
  • Source
    Jing Shi · Jianhua Tong · Shuang Cai · Xiujuan Qu · Yunpeng Liu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent investigations have suggested that common genetic polymorphisms in BRCA1-associated C-terminal helicase 1 (BACH1) are important in the development of breast cancer. However, individually published studies and previous meta-analyses have demonstrated inconclusive results. The aim of this meta-analysis was to derive a more precise estimation of the correlation between a common polymorphism [proline (Pro) 919 serine (Ser); rs4986764 C>T] in the BACH1 gene and susceptibility to breast cancer. A literature search of PubMed, Embase, Web of Science and Chinese BioMedicine (CBM) databases was conducted on articles published prior to March 1, 2013. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Eleven case-control studies were included with a total of 6,903 breast cancer cases and 8,154 healthy controls. The meta-analysis results revealed that the BACH1 919Ser polymorphism may be correlated with a decreased risk of breast cancer among Caucasian populations (Ser allele versus Pro allele: OR=0.90, 95% CI=0.86-0.95; Pro/Ser + Ser/Ser versus Pro/Pro: OR=0.90, 95% CI=0.84-0.98; Ser/Ser versus Pro/Pro + Pro/Ser: OR=0.84, 95% CI=0.76-0.92; Ser/Ser versus Pro/Pro: OR=0.81, 95% CI=0.73-0.91; Ser/Ser versus Pro/Ser: OR=0.86, 95% CI=0.78-0.95), although not among Asian populations. Further subgroup analyses indicated that there were significant correlations between the BACH1 919Ser polymorphism and a decreased risk of breast cancer in postmenopausal females, females with a family history of breast cancer and females without BRCA1/2 mutations. Univariate and multivariate meta-regression analyses revealed that none of the factors explained the heterogeneity (all P>0.05). The present meta-analysis suggested that the BACH1 919Ser polymorphism may decrease the risk of breast cancer among Caucasian populations, particularly in postmenopausal females with a family history of breast cancer and without BRCA1/2 mutations.
    Experimental and therapeutic medicine 08/2013; 6(2):435-444. DOI:10.3892/etm.2013.1148 · 1.27 Impact Factor
  • Source
    Lei Wang · Zan Teng · Shuang Cai · Difei Wang · Xin Zhao · Kai Yu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The polymorphism Pro12Ala in peroxisome proliferator-activated receptorgamma2 gene (PPARgamma2) has been reported to be associated with diabetic nephropathy (DN) in some studies, though the results remain inconclusive. To explore this relationship between PPARgamma2 Pro12Ala polymorphism and the susceptibility for DN, a cumulative meta-analys is was performed in this study. PubMed, Medline, Embase and Web of Science databases have been systematically searched to identify relevant studies. Odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated. 18 studies were included in this meta-analysis, involving 3,361 cases and 5,815 controls. The PPARgamma2 Ala12 allele was significantly associated with decreased risk of DN based on dominant model (OR=0.778; 95%CI=0.618-0.981; Pheterogeneity=0.008; P=0.034). In the stratified analysis by ethnicity, significantly decreased risks were found among Caucasians for dominant model (OR=0.674; 95%CI=0.500-0.909; Pheterogeneity=0.079; P=0.010), while there was no significant association was found in Asians. The results from the present meta-analysis indicated that the Pro12Ala polymorphism in PPARgamma2 gene is not a risk factor for DN in type 2 diabetes (T2D). Further large and well-designed studies are needed to confirm this conclusion. Virtual slides: The virtual slides for this article can be found here:
    Diagnostic Pathology 07/2013; 8(1):118. DOI:10.1186/1746-1596-8-118 · 2.60 Impact Factor
  • Source
    Zan Teng · Lei Wang · Shuang Cai · Ping Yu · Jin Wang · Jing Gong · Yunpeng Liu ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The 677C>T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene is considered to have a significant effect on colorectal cancer susceptibility, but the results are inconsistent. In order to investigate the association between the MTHFR 677C>T polymorphism and the risk of colorectal cancer, a meta-analysis was held based on 71 published studies. Eligible studies were identified through searching the MEDLINE, EMBASE, PubMed, Web of Science, Chinese Biomedical Literature database (CBM) and CNKI database. Odds ratios (OR) and 95% confidence intervals (CIs) were used to assess the association. The statistical heterogeneity across studies was examined with x(2)-based Q-test. Begg's and Egger's test were also carried out to evaluate publication bias. Sensitive and subgroup analysis were also held in this meta-analysis. Overall, 71 publications including 31,572 cases and 44,066 controls were identified. The MTHFR 677 C>T variant genotypes are significantly associated with increased risk of colorectal cancer. In the stratified analysis by ethnicity, significantly increased risks were also found among Caucasians for CC vs TT (OR = 1.076; 95%CI = 1.008-1.150; I(2) = 52.3%), CT vs TT (OR = 1.102; 95%CI = 1.032-1.177; I(2) = 51.4%) and dominant model (OR = 1.086; 95%CI = 1.021-1.156; I(2) = 53.6%). Asians for CC vs TT (OR = 1.226; 95%CI = 1.116-1.346; I(2) = 55.3%), CT vs TT (OR = 1.180; 95%CI = 1.079-1.291; I(2) = 36.2%), recessive (OR = 1.069; 95%CI = 1.003-1.140; I(2) = 30.9%) and dominant model (OR = 1.198; 95%CI = 1.101-1.303; I(2) = 52.4%), and Mixed populations for CT vs TT (OR = 1.142; 95%CI = 1.005-1.296; I(2) = 0.0%). However, no associations were found in Africans for all genetic models. This meta-analysis suggests that the MTHFR 677C>T polymorphism increases the risk for developing colorectal cancer, while there is no association among Africans found in subgroup analysis by ethnicity.
    PLoS ONE 02/2013; 8(2):e55332. DOI:10.1371/journal.pone.0055332 · 3.23 Impact Factor
  • Shuang Cai · Lei Wang ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A simple and rapid high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method has been developed and validated for the determination of 4-p-anisamidobutyric acid (ABA; or N-anysoyl-γ-aminobutiryc acid, N-anisoyl-GABA), a major active metabolite of aniracetam, in human plasma. After protein precipitation of plasma sample with methanol, ABA and the internal standard lisinopril were separated on a Venusil ASB C₁₈ column at 25 °C. The mobile phase consisted of methanol-ammonium acetate (10 mmol/L) (30:70, v/v). The detection was performed on a triple quadrupole tandem mass spectrometer with an ESI source in negative ion mode. Multiple reaction monitoring (MRM) using the precursor→product ion combinations of m/z 235.8→m/z 106.6, and m/z 403.8→m/z 113.6 was used to quantify ABA and lisinopril, respectively. This is the first LC-MS/MS method for ABA with advantages of short analysis time (4.5 min per sample run) and high selectivity attributable to the MRM detection and optimized HPLC conditions. The response was linear in a concentration range of 0.0485-19.4 μg/mL in plasma. The extraction recovery of ABA was between 89.1% and 100.7%. The precision (RSD) and accuracy (RE) of the method were evaluated to be within 7.3% and from 2.5% to 6.9%. The validated method has been applied to the pharmacokinetic study after a single oral administration of aniracetam dispersible tablets to human beings.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 04/2012; 897:50-4. DOI:10.1016/j.jchromb.2012.04.007 · 2.73 Impact Factor

Publication Stats

47 Citations
16.04 Total Impact Points

Top co-authors View all


  • 2013
    • Southern Medical University
      Shengcheng, Guangdong, China
  • 2012-2013
    • China Medical University (PRC)
      Feng-t’ien, Liaoning, China

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.